MONTPELLIER, FRANCE – Cilcare, a clinical-stage biotechnology company specializing in auditory sciences and the development of novel therapies for inner ear diseases, has announced the appointment of Dr. Naimi Missoum as Chief Medical Officer. Dr. Missoum, a Medical Doctor with over 25 years of experience as a senior executive in medical affairs at leading pharmaceutical companies, will oversee all of Cilcare’s medical initiatives, including clinical development strategies and collaborations with healthcare professionals and regulatory authorities.
Dr. Missoum, a surgeon specialized in ENT disorders, spent over a decade in hospital settings, working in both surgical interventions and diagnostic practices before transitioning to the pharmaceutical industry. His career includes leading roles at prestigious pharmaceutical companies, most recently serving as Global Medical Affairs Executive Director at Biogen, and significant experiences at BMS, MSD China, and AstraZeneca.
Throughout his career, Dr. Missoum has successfully developed and implemented medical affairs strategies in global markets, contributing to the launch of innovative medicines across various therapeutic areas, including Diabetes, Cardio-metabolism, Neurology, and Alzheimer’s disease. His expertise includes designing and executing late-stage clinical development phase 3b/4 studies, establishing life cycle management strategies, and developing patient registry networks. His strong scientific relationships with key opinion leaders make him a valuable addition to Cilcare’s team, aligning with the company’s focus on inner ear disorders, diabetes, and CNS diseases.
Cilcare CEO Celia Belline highlighted Dr. Missoum’s appointment as a significant moment in the company’s growth, noting his enlightened leadership and ability to inspire the medical team.
“Dr. Missoum’s appointment comes at a pivotal moment as Cilcare expands its clinical trial activity. With the launch of a second observational clinical trial in Alzheimer’s and Parkinson’s patients to define the presence of cochlear synaptopathy, and the preparation of Phase 2a for assessing our lead compound, CIL001, in the treatment of this form of hearing impairment, Dr. Missoum’s leadership will be instrumental in driving our mission forward.”
–Celia Belline, Cilcare CEO
Dr. Missoum expressed his enthusiasm for his new role, stating, “I am honored to join Cilcare as Chief Medical Officer. I am passionate about empowering global pharmaceutical projects led by biotech companies to turn their visions into impactful solutions. Together, we can shape a future of transformative solutions in preventive, predictive, and personalized medicine, making a lasting impact on healthcare.
“Cilcare is at the forefront of innovation in auditory sciences, and I look forward to contributing to the company’s mission to improve the lives of people with hearing issues and associated disorders.”
About Cilcare:
Cilcare is a biotechnology company focused on harnessing auditory sciences for the early definition, detection, and treatment of synaptopathy in neurocognitive and inflammatory diseases. Located in Montpellier and the Boston area (USA), Cilcare is developing its own portfolio of drug candidates using next-generation AI (Artificial Intelligence) and RWD (Real-World Data) platforms. The company combines unique expertise in preclinical development with the ability to translate generated data into clinical development strategies. Since 2014, Cilcare has accelerated drug development in hearing disorders by providing its smart R&D platform as a research-for-hire service to top hearing research companies and academic institutions in the US, Europe, and Asia.
Source: Cilcare
